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Abstract
Unknown primary malignancy in the head and neck is not an infrequent diagnosis for patients with
metastatic cervical lymph nodes. Although linked with a relatively good prognosis following
radiation treatment, widespread radiation is coupled with significant morbidity. Altered microRNA
(miRNA) expression has been associated with both cancer progression and metastasis. We sought
to determine whether miRNA expression analysis could be used as a diagnostic tool to discover
the primary site of malignancy, within the head and neck. We used quantitative real-time PCR to
identify miRNA expression profiles of squamous cell carcinoma of the tonsil, base of tongue and
post-nasal space, as well as their corresponding metastatic lymph nodes, from 6 patients. Our
results revealed that each cancer maintained its expression profile between the primary site and
the nodal metastasis (r = 0.82, p < 0.0001). In addition, each anatomical sub-site maintained a
distinct miRNA profile between individual patients (r = 0.79, p < 0.0001). Finally, between sub-sites,
the miRNA profiles were distinct (p < 0.0001). As proof of principle, our study provides an
indication that miRNA expression analysis may be useful to compare the primary lesion and local
metastatic disease. This may be clinically relevant to predict the primary site of origin of metastatic
disease, when the primary site remains obscure.
Findings
Cancer of unknown primary site is defined as a histologi-
cally confirmed metastasis in the absence of an identifia-
ble primary tumour, despite a standardized diagnostic
approach [1]. Within the head and neck, up to 10% of
metastatic squamous cell carcinoma has an unknown pri-
mary site, despite extensive diagnostic investigations [2].
Positron emission tomography (PET) scanning has
helped reduce this number [3]. Patients with a known pri-
mary site have a better prognosis [2]. This may be because
if the origin of the disease is known, specific therapeutic
regimes can be used, including reduced radiation fields,
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thereby minimizing therapy associated morbidity. In con-
trast, a widespread radiation field used in unknown pri-
mary disease is associated with increased morbidity.
Patients presenting with metastatic disease within their
cervical lymph nodes frequently have their primary dis-
ease within one of three sites; the tonsil, the base of
tongue (BOT) or the post nasal space (PNS). However,
despite a thorough clinical history and examination,
including biopsies, the primary site of disease may remain
concealed.
microRNA (miRNA) are approximately 22 nucleotides,
non-coding RNA molecules that bind to complementary
messenger RNA (mRNA) and regulate post-transcrip-
tional gene expression by either degrading mRNA or
inhibiting its translation. It has been estimated that the
number of miRNAs present in the human genome is
approximately 1000 [4]; to date, 677 were identified
(miRBase, The Sanger Institute) and they are predicted to
regulate at least 30% of mRNA transcripts [5,6]. miRNA
function in concert with tumor suppressors and oncopro-
teins to regulate key cellular pathways involved in devel-
opment, differentiation and tumorigenesis [7-9]. miRNA
expression profiling of human tumors has identified sig-
natures associated with diagnosis, staging, progression,
prognosis, and response to treatment [6,10]. Importantly,
miRNAs also appear to be a molecular-fingerprint that
may help predict the primary site of metastatic disease
[11].
In this study, we investigated miRNA expression from pri-
mary cancer (tonsil, BOT and PNS) and their correspond-
ing metastatic cervical lymph nodes to determine the
similarity of miRNA profiles between the primary and
metastatic lesions. Such miRNA profiles may be clinically
useful to help predict the primary site of disease.
This study was approved by the University Health Net-
work Research Ethics Board (07-0511-TE). The cancer reg-
istry was used to identify patients with biopsy proven
head and neck squamous cell carcinoma (HNSCC) with
regional cervical lymphadenopathy. Formalin-fixed paraf-
fin-embedded (FFPE) specimens from both the primary
site (tonsil, base of tongue and post-nasal space) and cor-
responding metastatic lymph node were sought from
Toronto General Hospital, Canada. We collected 12 tissue
samples from 6 patients (2 samples/patient) for the train-
ing set. An additional 6 patients (N = 12 samples) were
collected for validation analysis. Clinical details are
described in Table 1.
Histopathological analysis of all tissues was performed by
a head and neck pathologist (IW) to ensure the presence
of carcinoma in at least 80% of each tissue section. Total
RNA was isolated and purified from all samples using the
RecoverAll™ Total Nucleic Acid Isolation Kit (Ambion,
Austin, TX, USA), according to the manufacturer's proto-
col. Samples were stored at -80°C and RNA quality and
quantity were evaluated by spectrophotometry.
We used the TaqMan Low Density Array (TLDA) Human
MicroRNA Panel and Multiplex RT Pools of eight 48-
miRNA sets (Applied Biosystems, Streetsville, ON, Can-
ada) for global miRNA expression analysis by quantitative
real-time PCR (QRT-PCR). Briefly, total RNA was con-
verted into specific cDNA derived from mature miRNAs,
and then quantified using the TaqMan miRNA assay by
QRT-PCR. The TLDA card contained 365 lyophilized
human miRNA sequences, plus three small nucleolar
RNAs (snoRNAs), RNU6B, RNU48 and RNU44, used as
endogenous controls. Data was quantified and analyzed
using the Sequence Detection System software (v. 2.3)
(Applied Biosystems). The relative expression of each
miRNA was normalized against endogenous controls
using the equation 2-ΔCt, where ΔCt = (CtmiRNA-CtsnoRNAs).
miRNA expression levels in primary tumour and lymph
nodes were calculated relative to a commercially available
Universal Reference RNA (Stratagene).
The pair-wise correlation coefficient of miRNA expression
between the primary tumor and corresponding lymph
node was significant for each patient (0.82, p < 0.0001),
indicating that miRNA expression remained consistent
between the primary lesion and local metastatic disease.
In addition, the correlation coefficient within the same
site, but between different patients, was 0.76 (p < 0.0001)
for the tonsil, 0.83 (p < 0.00001) for the BOT and 0.90 (p
< 0.0001) for the PNS. Overall, the similarity between
patients in each sub-site was 0.79 (p < 0.0001). These data
were subjected to Principal Component Analysis (PCA)
using Partek® Genomics Suite software, version 6.4 Copy-
right© 2009, Partek Inc., St Louis, MO, USA [12]. Figure 1
shows the PCA and expression values for 5 representative
miRNAs, which were significantly differentially expressed
across samples.
We next identified the top miRNA expression values with
the greatest similarity within each sub-site, totaling 75
miRNAs, using residual sum of squares (RSS: 0.0008-
0.01). A total of 12 out of 75 miRNAs were common
between any 2 sub-sites combined. Excluding these 12
overlapping miRNAs, a total of 63 were then used to com-
pare the miRNA expression profile between the three pri-
mary sites (tonsil, BOT and PNS) (figure 2). The mixed
model regression analysis showed a significant difference
between miRNA profiles from tonsil, BOT and PNS (p <
0.0001), suggesting that discrete anatomical locations
within the head and neck expressed distinct miRNA pro-
files. The pair-wise difference between tonsil and PNS wasMolecular Cancer 2009, 8:127 http://www.molecular-cancer.com/content/8/1/127
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p < 0.0001; tonsil and BOT was p = 0.14; and PNS and
BOT was p = 0.0006.
We performed QRT-PCR validation analysis, as previously
reported by our group [13]. We selected 5 miRNAs for val-
idation (miR-103, miR-155, miR-181b, miR-181d, and
miR-191); these miRNAs were selected based on their
similar expression levels in primary tumor and metastatic
tissues, among the distinct subsites. RNU44 was used as
endogenous control. Gene expression values were calcu-
lated using the ΔΔCt method. We confirmed that miR-155
was highly expressed in all samples, regardless of tumor
site (Median expression level = 36.9) relative to Human
Universal RNA (expression = 1); miR-181b and miR-181d
were similarly expressed (Median expression = 1.1, for
both). Increased expression levels were confirmed for
miR-103 (Median = 1.4) and miR-191 (Median = 4.4), as
compared to the Universal RNA (figure 3). Interestingly,
one lymph node metastasis sample (Pt. 11, NPC) showed
under-expression of all these 5 miRNAs, suggesting the
need for further examining the biological significance of
deregulated miRNA expression in primary tumours and
their metastases.
Overall, miRNA expression patterns may be site specific
within the head and neck (e.g, tongue vs. nasopharynx).
The embryological events that result in the formation of
the head and neck may be the reason why distinct ana-
tomical sites contain dissimilar miRNA profiles. In brief,
the posterior tongue arises from the third pair of branchial
or pharyngeal arches. In contrast, the tonsil originates
from the second pouch endoderm (forming the surface
epithelium and the lining of the crypts of the palatine ton-
sil) and the mesenchyme around the crypts differentiates
into lymphoid tissue that organizes into the lymphatic
nodule of the palatine tonsil. The nasopharynx is more
indistinct and is derived from both the first and second
arches. It has been shown that different tumour types have
Table 1: Patient clinical data.
Patient Age Sex Tobacco Alcohol Primary Tumor Site Tumor Grade Stage Outcome Last FU
Training set
1 55 F Y Y Tonsil PD T1N1 AWD 05/2004
2 44 F N/A N/A Tonsil MD T1N2 ANED 05/2001
3 73 M Former Y* BOT PD T1N2 ANED 03/2000
4 56 M N Y* BOT MD T1N2 ANED 11/2009
5 44 F N N PNS NPC T4N1 ANED 04/2009
6 41 M N Y* PNS NPC T2N2 ANED 08/2009
Validation set
7 61 M Y Y Tonsil MD T2N2b ANED 09/2009
8 63 M Y Y Tonsil MD T2N0 ANED 05/2009
95 8 M N Y * B O T P D T 1 N 2 b A N E D 1 0 / 2 0 0 9
10 47 F N N BOT MD TxN3 ANED 08/2009
11 57 M Y N PNS NPC T1N2 ANED 07/2009
12 56 M Y N/A PNS NPC T1N3 ANED 05/2009
Former: patient quit smoking in 1984; Alcohol; Y*: occasional drinker
BOT: base of tongue; PNS: post-nasal space
PD: poorly differentiated; MD: moderately differentiated
AWD: Alive with disease; ANED: Alive with no evidence of disease
FU: Follow-up (Month/Year)
None of the patients have had previous irradiation.Molecular Cancer 2009, 8:127 http://www.molecular-cancer.com/content/8/1/127
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distinct patterns of miRNA expression and this profile
reflects the developmental origin of the tissue [11]. In
addition, within a single developmental cell lineage, dis-
tinct patterns of miRNA expression can also be observed,
representing different mechanisms of transformation
such as chemical or viral carcinogens [11]. Lu et al [11]
used miRNA expression to define non-head and neck,
poorly differentiated tumours when the histology was not
diagnostic. 12/17 patients were diagnosed correctly in
contrast to 1/17 when a mRNA-based classifier was used.
Another advantage of a miRNA centered diagnostic tool is
that, in contrast to mRNA, miRNA is not degraded in for-
malin-fixed, paraffin-embedded clinical tissues. In addi-
tion, miRNA may be important for both diagnostic and
prognostic purposes: miRNA over-expression was found
associated with oral carcinoma progression [13] and
changes in miRNA levels were correlated with survival in
lung carcinoma [14].
miRNAs are known to be important in HNSCC [15-17]
including tongue [18,19] and nasopharyngeal [20] carci-
nomas. hsa-miR-205 has been shown to be highly
expressed in HNSCC cell lines but not in lung, breast,
colorectal, prostate or pancreatic cell lines [16]. In addi-
tion, hsa-miR-205 was over-expressed in tonsillar carci-
noma compared with normal tonsil (unpublished data
Principal component analysis based on the differential expression levels of 5 miRs (miR-137, miR-210, miR-200c, miR-213, and  miR-622) Figure 1
Principal component analysis based on the differential expression levels of 5 miRs (miR-137, miR-210, miR-
200c, miR-213, and miR-622). These miRs showed the most significant differential expression according to each tumor site. 
The dot plots represent the relative expression levels of each miR across all sites.
PCA MappingMolecular Cancer 2009, 8:127 http://www.molecular-cancer.com/content/8/1/127
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from same authors). In our analysis, has-miR-205 showed
very high expression levels in both primary tumour and
metastatic disease from all subsites. Interestingly, hsa-
miR-205 over-expression was recently shown to be spe-
cific for detection of metastatic disease in head and neck
carcinoma [21]. In contrast with our results, Tran et al [16]
showed an absence of site-specific miRNA expression pro-
file between the tongue, oropharyngeal and laryngeal can-
cer cell lines. This difference could be attributed to the fact
that potentially, cell lines express different miRNA expres-
sion profiles than either normal tissue or an associated
tumour.
We were interested to determine if miRNA expression
could afford a diagnostic advantage. In thyroid malig-
nancy, miRNA expression analysis is currently being
investigated as a diagnostic tool [22-25]. Specifically,
miR-146b is over-expressed in papillary carcinoma, but
benign pathology reveals a lower expression for this
miRNA [24]. In this study, miRNA was successfully
extracted from fine needle aspirates (FNA).
Ultimately, in the unknown primary setting, we would
propose to aspirate cells (FNA) from the neck node and
use cells for miRNA analysis. Over time, a bank of expres-
sion profiles from both normal tissue (from healthy sub-
jects) and carcinoma from each sub-site would be formed
Venn diagram showing the top most similar miRNAs within each anatomical sub-site (BOT: base of tongue, PNS: post nasal  space) Figure 2
Venn diagram showing the top most similar miRNAs within each anatomical sub-site (BOT: base of tongue, 
PNS: post nasal space).
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and used to help determine the most likely primary site of
disease.
In summary, this is the first study to evaluate the use of
miRNA as a diagnostic aid to predict the origin of an
unknown primary tumour in the head and neck. We
showed that the miRNA expression profile between the
primary lesion and local metastatic disease remains con-
sistent for an individual patient and between different
patients within an individual site. In addition, the analysis
of a subgroup of similarly expressed miRNAs within each
site showed that each primary site has a distinct miRNA
expression profile. In the future, miRNA expression profil-
ing analysis may help predict the site of origin of the met-
astatic disease, when the primary site remains clinically
obscure. This will potentially lead to improved patient
management and decreased morbidity.
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